Literature DB >> 11509592

Exogenous peptides presented by transporter associated with antigen processing (TAP)-deficient and TAP-competent cells: intracellular loading and kinetics of presentation.

T Luft1, M Rizkalla, T Y Tai, Q Chen, R I MacFarlan, I D Davis, E Maraskovsky, J Cebon.   

Abstract

This study investigates the differential capacity of TAP-deficient T2 cells, TAP-competent EBV cells, and immature and mature dendritic cells to present peptides to preformed CTL lines. It demonstrates that presentation of exogenous peptides involves peptide uptake and loading onto newly synthesized MHC class I molecules. This mechanism was best demonstrated for low affinity peptides in the presence of irrelevant peptides competing for HLA binding sites. Under these circumstances, inhibition of protein synthesis with cycloheximide or vesicular trafficking with brefeldin A significantly reduced the presentation of low affinity peptides. This was not restored by adding exogenous beta(2)-microglobulin to stabilize the MHC complex on the cell surface. In contrast, presentation of high affinity peptides was not sensitive to cycloheximide or brefeldin A, which suggests that different mechanisms may operate for presentation of high and low affinity peptides by TAP-competent cells. High affinity peptides can apparently compete with peptides in preloaded MHC class I molecules at the cell surface, whereas low affinity peptides require empty MHC molecules within cells. Accordingly, very high concentrations of exogenous low affinity peptides in conjunction with active MHC class I metabolism were required to allow successful presentation against a background of competing intracellular high affinity peptides in TAP-competent cells. These findings have implications for the design of peptide and protein-based vaccines.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11509592     DOI: 10.4049/jimmunol.167.5.2529

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  18 in total

1.  Cytotoxic T-lymphocyte responses to human papillomavirus type 16 E5 and E7 proteins and HLA-A*0201-restricted T-cell peptides in cervical cancer patients.

Authors:  Dai-Wei Liu; Yuh-Cheng Yang; Ho-Fan Lin; Mei-Fang Lin; Ya-Wen Cheng; Chen-Chung Chu; Yeou-Ping Tsao; Show-Li Chen
Journal:  J Virol       Date:  2007-01-03       Impact factor: 5.103

2.  The C terminus of the nucleoprotein of influenza A virus delivers antigens transduced by Tat to the trans-golgi network and promotes an efficient presentation through HLA class I.

Authors:  Francesca Bettosini; Maria Teresa Fiorillo; Adriana Magnacca; Laura Leone; Maria Rosaria Torrisi; Rosa Sorrentino
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

3.  In silico and cell-based analyses reveal strong divergence between prediction and observation of T-cell-recognized tumor antigen T-cell epitopes.

Authors:  Julien Schmidt; Philippe Guillaume; Danijel Dojcinovic; Julia Karbach; George Coukos; Immanuel Luescher
Journal:  J Biol Chem       Date:  2017-05-23       Impact factor: 5.157

4.  A similarity in peptide cross-reactivity between alloantigen- and nominal antigen-induced CD8+ T cell responses in vitro.

Authors:  Qian Yu; Li Zhang; Lichen Ouyang; Yeli Gong; Zhihui Liang; Guanxin Shen; Xiufang Weng; Xiongwen Wu
Journal:  Immunogenetics       Date:  2012-12-12       Impact factor: 2.846

5.  Directed evolution of human T cell receptor CDR2 residues by phage display dramatically enhances affinity for cognate peptide-MHC without increasing apparent cross-reactivity.

Authors:  Steven M Dunn; Pierre J Rizkallah; Emma Baston; Tara Mahon; Brian Cameron; Ruth Moysey; Feng Gao; Malkit Sami; Jonathan Boulter; Yi Li; Bent K Jakobsen
Journal:  Protein Sci       Date:  2006-04       Impact factor: 6.725

Review 6.  Current tools for predicting cancer-specific T cell immunity.

Authors:  David Gfeller; Michal Bassani-Sternberg; Julien Schmidt; Immanuel F Luescher
Journal:  Oncoimmunology       Date:  2016-04-25       Impact factor: 8.110

7.  Stable, Nonviral Expression of Mutated Tumor Neoantigen-specific T-cell Receptors Using the Sleeping Beauty Transposon/Transposase System.

Authors:  Drew C Deniger; Anna Pasetto; Eric Tran; Maria R Parkhurst; Cyrille J Cohen; Paul F Robbins; Laurence Jn Cooper; Steven A Rosenberg
Journal:  Mol Ther       Date:  2016-03-05       Impact factor: 11.454

8.  Generation of MANAbodies specific to HLA-restricted epitopes encoded by somatically mutated genes.

Authors:  Andrew D Skora; Jacqueline Douglass; Michael S Hwang; Ada J Tam; Richard L Blosser; Sandra B Gabelli; Jianhong Cao; Luis A Diaz; Nickolas Papadopoulos; Kenneth W Kinzler; Bert Vogelstein; Shibin Zhou
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-27       Impact factor: 11.205

9.  Antitumor activity of a monoclonal antibody targeting major histocompatibility complex class I-Her2 peptide complexes.

Authors:  Rinki Jain; Amit Rawat; Bhavna Verma; Maciej M Markiewski; Jon A Weidanz
Journal:  J Natl Cancer Inst       Date:  2013-01-08       Impact factor: 13.506

10.  Processing and presentation of exogenous HLA class I peptides by dendritic cells from human immunodeficiency virus type 1-infected persons.

Authors:  Xiao-Li Huang; Zheng Fan; Bonnie A Colleton; Rico Buchli; Hongyi Li; William H Hildebrand; Charles R Rinaldo
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.